- Conditions
- Lung Cancer
- Interventions
- DNA/RNA sequencing and expression levels, Protein expression analysis, Lung tumor biopsy, Blood sample
- Genetic · Procedure
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- Up to 120 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2017
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 745–768
of 80,955
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Melanoma
- Interventions
- Anakinra, Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Tocilizumab
- Biological · Procedure · Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Lumbar Puncture, Topical Analgesia
- Interventions
- J-Tip, EMLA, Lidocaine
- Device · Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Chronic Exertional Compartment Syndrome
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Ischemic Stroke
- Interventions
- Q Therapeutic System (BQ 3.0) - Sham, Q Therapeutic System (BQ 3.0) - Active
- Device
- Lead sponsor
- BrainQ Technologies Ltd.
- Industry
- Eligibility
- 22 Years to 80 Years
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 14
- States / cities
- Downey, California • Washington D.C., District of Columbia • Jacksonville, Florida + 11 more
- Conditions
- Adenocarcinoma of the Colon, Stage III Colon Cancer
- Interventions
- irinotecan hydrochloride, oxaliplatin, leucovorin calcium, fluorouracil, cetuximab, Locally Directed Therapy
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 3,397 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 858
- States / cities
- Anniston, Alabama • Huntsville, Alabama • Mobile, Alabama + 538 more
- Conditions
- Diabetes Mellitus, Type 2, Impaired Renal Function
- Interventions
- Dapagliflozin 10 MG [Farxiga]
- Drug
- Lead sponsor
- Emerald Clinical Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Discontinuing Bruton tyrosine kinase inhibitors (BTKi) therapy
- Other
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Osteoarthritis
- Interventions
- CR845 0.25 mg, CR845 0.50 mg, CR845 1 mg, CR845 5 mg
- Drug
- Lead sponsor
- Cara Therapeutics, Inc.
- Industry
- Eligibility
- 25 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 5
- States / cities
- Omaha, Nebraska • Las Vegas, Nevada • Greensboro, North Carolina + 2 more
- Conditions
- Paroxysmal Supraventricular Tachycardia
- Interventions
- Etripamil NS 70 mg, Aptar Pharma Nasal Spray Bidose System
- Drug · Device
- Lead sponsor
- Milestone Pharmaceuticals Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 17
- States / cities
- Little Rock, Arkansas • Vista, California • West Hills, California + 14 more
- Conditions
- Advanced Parkinson's Disease
- Interventions
- Not listed
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Boca Raton, Florida • Gainesville, Florida + 16 more
- Conditions
- Breast Cancer, Metastatic Breast Cancer (MBC)
- Interventions
- Romosozumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
- Interventions
- paclitaxel, cisplatin, topotecan hydrochloride, filgrastim
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1996
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Atrial Fibrillation
- Interventions
- Not listed
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 62
- States / cities
- Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 52 more
- Conditions
- Marfan Syndrome
- Interventions
- Exercise
- Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 10 Years to 19 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Stress
- Interventions
- Therapeutic exercises
- Other
- Lead sponsor
- Dylan Saulsbery
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Refractory Malignancies
- Interventions
- NRX 194204
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Interventions
- carfilzomib, dexamethasone, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 3
- States / cities
- Duarte, California • Rochester, Minnesota • St Louis, Missouri
- Conditions
- Myalgic Encephalomyelitis, Long-COVID
- Interventions
- Rapamycin
- Drug
- Lead sponsor
- Simmaron Research Inc.
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 5
- States / cities
- Palo Alto, California • Rochester, Minnesota • Incline Village, Nevada + 2 more
- Conditions
- IBD (Inflammatory Bowel Disease), IBD, IBD - Inflammatory Bowel Disease
- Interventions
- Confocal Laser Endomicroscopy
- Device
- Lead sponsor
- Cook Children's Health Care System
- Other
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Arlington, Texas • Fort Worth, Texas
- Conditions
- Sarcoma
- Interventions
- soblidotin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 15 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Indianapolis, Indiana • New York, New York + 1 more
- Conditions
- Type 2 Diabetes
- Interventions
- Blood Draw
- Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Chronic Disease
- Interventions
- Conversation Game
- Behavioral
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Sotagliflozin, Placebo
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 15
- States / cities
- Tustin, California • Aurora, Colorado • New Haven, Connecticut + 12 more